Cerebrolysin is the porcine-brain-derived multi-component peptide preparation manufactured by Ever Neuro Pharma (Austria) and used clinically in Russia, China, some CIS and Central/Eastern European countries, and elsewhere for neurological indications including vascular dementia, Alzheimer's disease, acute ischaemic stroke, and traumatic brain injury. The compound's international clinical-trial evidence base is the broadest of any of the Russian/CIS multi-component neuropeptide-preparation family.

Cochrane systematic-review analyses have been completed for multiple Cerebrolysin indications, providing the strongest independent methodological synthesis of the underlying primary trial evidence available for any of the multi-component neuropeptide preparations covered on this reference.

The Cochrane systematic-review analyses of Cerebrolysin in acute ischaemic stroke reviewed multiple randomised-controlled trials with a total pooled sample of several thousand patients. The primary endpoint was neurological outcome measured by standard stroke-outcome scales.

The Cochrane conclusion for acute ischaemic stroke was that Cerebrolysin does not produce clinically significant improvements in neurological outcome compared with placebo or standard care, though safety endpoints were acceptable. The specific effect estimates on primary outcomes were small and did not reach the threshold for clinical significance.

The finding was consistent with the general Cochrane framework's stringent evidence-standard requirements for demonstrating clinical benefit.

The Cochrane systematic-review analyses of Cerebrolysin in vascular dementia reviewed multiple randomised-controlled trials with the primary endpoint being cognitive-outcome measures. The pooled results reported modest cognitive-endpoint improvements in the Cerebrolysin arm, though the effect sizes were small and the trial methodology was mixed.

The Cochrane conclusion was that the evidence base was insufficient to support Cerebrolysin as a licensed vascular dementia treatment in Western regulatory frameworks, though the direction of effect was consistent with the compound's continued clinical use in the approving jurisdictions.

The Cochrane analyses of Cerebrolysin in Alzheimer's disease reviewed a smaller number of RCTs with cognitive and functional endpoints. Effect estimates were modest and mixed across the included trials.

The Cochrane conclusion was similar to the vascular dementia and acute stroke conclusions — evidence insufficient to support Cerebrolysin as a licensed Alzheimer's disease treatment in Western regulatory frameworks, though the direction of some cognitive-endpoint results was consistent with continued clinical use in approving jurisdictions.

The Cerebrolysin Cochrane analyses provide the strongest independent methodological synthesis available for any of the multi-component neuropeptide-preparation family. The consistent conclusion across indications is that the evidence base is not strong enough by Western regulatory-science standards to support licensed clinical use, but the pattern of effect direction is not incompatible with the compound's continued clinical use in the approving jurisdictions.

The gap between 'consistent positive signal in Russian/international trials' and 'meets MHRA or FDA standard for licensing' is meaningful and non-trivial — a pattern shared across the entire Russian/CIS multi-component neuropeptide-preparation family. For UK-based research and clinical purposes, Cerebrolysin remains a non-licensed compound; use is restricted to research-context arrangements under appropriate ethical and regulatory framework.